Agent for promoting or ameliorating endometrial deciduation

By promoting endometrial decidualization and placental trophoblast cell fusion through pyrroloquinoline quinone (PQQ), the problem of infertility caused by abnormal endometrial decidualization was solved, and fertility was improved.

CN122295102APending Publication Date: 2026-06-26HIROSHIMA UNIVERSITY +2
2 Cites 0 Cited by

Patent Information

Application Number
CN202480075517.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-11-30
Filing Date
2024-11-29
Publication Date
2026-06-26

AI Technical Summary

Technical Problem

In current infertility treatments, abnormal decidualization of the endometrium leads to implantation problems or miscarriage, and existing assisted reproductive technologies have failed to effectively address the complex physiological phenomena between the ovaries, fallopian tubes, and uterus, making it difficult to eradicate infertility.

Method used

Using pyrroloquinoline quinone (PQQ) as the active ingredient, it is administered orally to promote endometrial decidualization, inhibit cell aging, promote placental trophoblast cell fusion, and improve fertility during a specific period starting from the first day of menstruation.

Benefits of technology

It significantly promotes endometrial decidualization, inhibits the expression of aging genes, improves implantation rate and implantation status, and enhances fertility.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides a preparation capable of promoting normal deciduation of endometrium. An agent for promoting or ameliorating endometrial deciduation, which contains an effective amount of pyrroloquinoline quinone or a salt thereof, is prepared. In addition, a cell fusion promoting or ameliorating agent containing an effective amount of pyrroloquinoline quinone or a salt thereof is prepared.
Need to check novelty before this filing date? Find Prior Art